SEC Tracker
Get the app
ADPT · XBRL financial data

Adaptive Biotechnologies financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ADPT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers3846*42434647*52599472*7172
Cost of goods and services sold1920*18191718*17181818*1920
Research and development2929*30252423*24242422*2419
General and administrative2021*20181718*17181820*2121
Operating income (loss)(51)(71)*(49)(47)(33)(34)*(30)(25)10(13)*(19)(16)
Interest expense43*3333*3333*33
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(50)(69)*(48)(46)(32)(34)*(30)(26)10(14)*(20)(40)
Earnings per share, basic USD per share(0.35)(0.48)*(0.33)(0.31)(0.22)(0.23)*(0.20)(0.17)0.06(0.09)*(0.13)(0.25)
Earnings per share, diluted USD per share(0.35)(0.48)*(0.33)(0.31)(0.22)(0.23)*(0.20)(0.17)0.06(0.10)*(0.13)(0.25)
Weighted average shares, basic millions of shares145145*146147148148*149152152153*156160
Weighted average shares, diluted millions of shares145145*146147148148*149152163142*156160

Balance sheet

CSV

Fiscal quarters (ADPT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents8965716038485143557078170
Marketable securities282281238232205174143155158156141174
Marketable securities, non-current————243439244131927
Accounts receivable313842364142444445504850
Inventory191413131289810101110
Prepaid and other current assets131110111211111114131416
Total current assets435410374352308284256262281300292421
Property and equipment, net776865555149444137343129
Right-of-use asset755251494746444342414039
Goodwill119119119119119119119119119119119119
Total assets718661620585559539511497491513506641
Accounts payable4812107767106105
Accrued liabilities10987688778711
Current portion of long-term debt3————1232560
Total current liabilities938883888898889283908788
Long-term debt1271311321321331321321301291271250
Lease liability, non-current928987848279767472706967
Total liabilities356353346343335337321317286288282490
Accumulated deficit(1,075)(1,144)(1,192)(1,238)(1,270)(1,304)(1,334)(1,359)(1,350)(1,363)(1,383)(1,423)
Total stockholders' equity362308275242224203190180204219216143
Total liabilities and equity718661620585559539511497491513506641
Common shares outstanding (cover page) millions of shares145145147147148149152152153154160160

Cash flows

CSV

Fiscal quarters (ADPT's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(50)(69)*(48)(46)(32)(34)*(30)(26)10(14)*(20)(40)
Stock-based compensation15*16*1413*14*13*1213*13*13*1211*
Net cash from operating activities(47)*(27)*(38)(17)*(27)*(12)*(28)(12)*(7)*2*(10)(6)*
Purchases of property and equipment3*1*22*0*0*11*0*1*11*
Net cash from investing activities26*3*456*5*22*263*17*(8)*9(43)*
Net cash from financing activities0*0*00*0*0*52*2*22*8142*
Net change in cash(21)*(24)*6(11)*(22)*10*3(7)*12*15*792*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Adaptive Biotechnologies17072(6.4)*159.6M53.8 quarters 10-QJun 30, 2026
Arrowhead Pharmaceuticals5575(177)*141.3M9.0 quarters 10-QJun 30, 2026
Travere Therapeutics12422598*96.0M— 10-QSep 30, 2026
Ani Pharmaceuticals36026657*not reported— 10-QJun 30, 2026
Celldex Therapeutics470(57)*78.5M12.5 quarters 10-QJun 30, 2026
Avadel Pharmaceuticals807722*97.7M— 10-QSep 30, 2025
Innoviva57012052*72.2M— 10-QJun 30, 2026
Ligand Pharmaceuticals5679(28)*20.0M— 10-QSep 30, 2026
Ocular Therapeutix59913(67)*219.6M8.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.